CANF — Can-Fite BioPharma Ltd.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1536196 ·
Last close
$3.35
Market Cap
$7.18M
52W High
$5.98
52W Low
$2.56
ADV30
81,425
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 9,514,000 | 5,528,000 | 3,922,000 |
| Jun 2025 | — | — | — | — | — | — | 3,536,000 |
| Dec 2024 | — | — | — | — | 9,120,000 | 4,825,000 | 3,684,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-176,189,000
Inventory
—
Receivables
—
ST Investments
$3,012,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$405,000
EBITDA
$-9,926,000
Free Cash Flow
$-4,985,750
Enterprise Value
$-1,334,320
Total Cash
$8,540,000
Total Debt
$71,000
Shares Out
2,142,547
Trailing EPS
$-10.75
Book Value
$4.27
ROE
-178.2%
ROA
-66.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 405,000 | -9,950,000 | -9,828,000 | 9,514,000 | 3,922,000 | — | -8,949,000 |
| Dec 2024 | 674,000 | -8,130,000 | -7,880,000 | 9,120,000 | 3,684,000 | — | -7,637,000 |
| Dec 2023 | 743,000 | -8,195,000 | -7,634,000 | 9,989,000 | 3,746,000 | — | -8,440,000 |
| Dec 2022 | 810,000 | -10,096,000 | -10,173,000 | 9,283,000 | 4,811,000 | — | -10,801,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.27
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| APUS | Apimeds Pharmaceuticals US, Inc. | $7.17M | $4.75 | — |
| BOLT | Bolt Biotherapeutics, Inc. | $7.20M | $3.74 | — |
| CURX | Curanex Pharmaceuticals Inc | $7.26M | $4.63 | — |
| ENSC | Ensysce Biosciences, Inc. | $7.02M | $0.36 | — |
| ALZN | Alzamend Neuro, Inc. | $7.43M | $1.55 | — |
News headlines (Yahoo Finance, 1h cache)
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
2026-08-17 11:00 · Yahoo
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
2026-08-12 11:00 · Yahoo
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
2026-08-03 11:00 · Yahoo
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
2026-07-20 11:00 · Yahoo
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
2026-07-14 11:00 · Yahoo
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
2026-07-06 11:00 · Yahoo
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
2026-07-01 11:00 · Yahoo
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
2026-06-26 11:00 · Yahoo
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
2026-06-22 11:00 · Yahoo
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
2026-06-17 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.